Roche Palo Alto LLC

Anacor Pharmaceuticals, Inc.

Curasen Therapeutics, Inc.

F. Hoffmann-la Roche Ag

David Scott Carter

Michael Patrick Dillon

Ronald Charles Hawley

Alam Jahangir

Chris Allen Broka

Daniel Warren Parish

Jacob J Plattner

Yong-Kang Zhang

Tsutomu Akama

Ryan Craig Schoenfeld

Robert Toms Jacobs

Yang Liu

Clara Jeou Jen Lin

Michael John Witty

Jason S Halladay

Wei P Chen

Jiaxin Yu

Robert James Weikert

Amy Geraldine Moore

Anthony P D W Ford

Eric Brian Sjogren

Matthew C Lucas

Jim W Li

Javier De Vicente Fidalgo

Francisco Xavier Talamas

Kenneth Albert Brameld

Wei Chen

Clara Jeou Lin

Jim Li

Anthony PDW Ford

The present disclosure is directed to chemical compounds and to the use of such compounds in the treatment of diseases associated with an adrenergic receptor. In certain embodiments of the methods disclosed herein, the methods include administering to the subject a compound as disclosed herein and a peripherally acting P-blocker (PABRA).

Beta adrenergic agonist and methods of using the same

The present invention provides oxaborole ester compounds and compositions thereof which are useful to treat diseases associated with parasites, such as Chagas Disease and African Animal Trypanosomosis.

Oxaborole esters and uses thereof

The present disclosure is directed to chemical compounds and to the use of such compounds in the treatment of diseases associated with an adrenergic receptor.

Compounds and methods for treating diseases mediated by a P2Xand/or a P2Xreceptor antagonist, the methods comprising administering to a subject in need thereof an effective amount of a compound of formula (I): or a pharmaceutically acceptable salt, solvate or prodrug thereof,wherein D, X, Y, R, R, R, R, R, R, Rand Rare as defined herein.

[object Object]

Compounds and methods for treating diseases mediated by a P2Xand/or a P2Xreceptor antagonist, the methods comprising administering to a subject in need thereof an effective amount of a compound of formula (I): or a pharmaceutically acceptable salt, solvate or prodrug thereof,

Methods for treating respiratory and gastrointestinal diseases mediated by a P2Xand/or a P2Xreceptor antagonist, the methods comprising administering to a subject in need thereof an effective amount of a compound of formula (I): or a pharmaceutically acceptable salt thereof,wherein D, X, Y, R, R, R, R, R, R, Rand Rare as defined herein.

Compounds having the formula I wherein R, R, R, R, R, R, R, R, Rand n are as defined herein are Hepatitis C virus NS5b polymerase inhibitors. Also disclosed are compositions and methods for treating an HCV infection and inhibiting HCV replication. 

Heterocyclic antiviral compounds

Methods for treating respiratory and gastrointestinal diseases mediated by a P2Xand/or a P2Xreceptor antagonist, the methods comprising administering to a subject in need thereof an effective amount of a compound of formula (I): or a pharmaceutically acceptable salt thereof,

Compounds of formula I: or pharmaceutically acceptable salts thereof, wherein Ar is indolyl, indazolyl or dihydroindolyl, and R, R, Rand Rare as defined herein. Also provided are pharmaceutical compositions, methods of using the compounds in the treatment of depressive, anxiolytic and other disorders associated with inhibition of the reuptake of norepinephrine, serotonin, and dopamine, and methods of preparing the compounds.

Arylpiperazine derivatives and uses thereof

Compounds of the formula: or pharmaceutically acceptable salts thereof,wherein m, n, X, Y, Z, Ar, R, R, R, R, R, Rand Rare defined herein. Also provided are pharmaceutical compositions, methods of using, and methods of preparing the compounds.

Growing community of inventors

Sunnyvale, CA, United States of America

David Scott Carter